about
The human fatty acid-binding protein family: evolutionary divergences and functionsS100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10S100A7 and the progression of breast cancerPsoriasin (S100A7) expression and invasive breast cancerExpression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiationSolution structure and backbone dynamics of human epidermal-type fatty acid-binding protein (E-FABP)Psoriasin (S100A7) expression is altered during skin tumorigenesisS100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breastExpression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomasCa(2+)-dependent association of S100A6 (Calcyclin) with the plasma membrane and the nuclear envelope.S100A7 (Psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells.S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.Nuclear S100A7 is associated with poor prognosis in head and neck cancer.Molecular and cellular impact of Psoriasin (S100A7) on the healing of human wounds.Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders.Expression of human protein S100A7 (psoriasin), preparation of antibody and application to human larynx squamous cell carcinomaPsoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation.Influence of calcium on the proteolytic degradation of the calmodulin-like skin protein (calmodulin-like protein 5) in psoriatic epidermis.Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo.Genetics and genomics of asthma and allergic diseases.Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans.Biological Markers Predictive of Invasive Recurrence in DCIS.Opposing Effects of Zac1 and Curcumin on AP-1-Regulated Expressions of S100A7Causes and consequences of DNA hypomethylation in human cancer.Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's diseaseExpression and clinical significance of S100A2 and p63 in esophageal carcinomaProstate transglutaminase: a unique transglutaminase and its role in prostate cancer.S100 proteins and the skin: a review.IGF-1 deficiency in combination with a low basic hBD-2 and hBD-3 gene expression might counteract malignant transformation in pleomorphic adenomas in vitro.Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity.Comparative proteomics analysis of primary cutaneous amyloidosisPsoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression.Current concepts in the pathogenesis of psoriasis.Microbicidal protein psoriasin is a multifunctional modulator of neutrophil activation.Suction blister fluid as potential body fluid for biomarker proteins
P2860
Q21245453-A18FB403-7695-450C-BFF8-390D75052C2AQ21562503-40615227-98BA-4AFD-BAA9-A72D30498ECDQ22000741-D91A8F1E-6567-472A-9351-697C2A29D5E2Q22010926-10E1EB9E-638F-4EEF-A656-761FFE5BE0DAQ24297169-F221E20F-9991-4D52-B079-8AFD0CED6E24Q24534139-1F8E49E7-9A30-4DB1-9651-786C6CE41D12Q24805365-37CCFC6F-D228-4275-903E-CB63F2C7CB5CQ24805971-CD774EF3-5771-46AF-9CD2-822CE7D6C6A1Q30445447-B00394FE-793E-4A3D-8C13-D752F6EE74DCQ30798710-92629FDE-9ADE-4437-A18C-6D364CAAFD7FQ33305131-D0A152C6-AA2B-4FDC-8E64-EC74803044B2Q33648661-36F88173-E5B0-4817-9C6A-D881517E7C31Q33651153-399C9A13-916E-4F3B-B1DF-E436A5C15EB1Q33724031-5851605A-3941-459E-930B-3BE686FFC8E7Q33737892-F4CCE09D-D3CF-472B-AD64-226FFC7A02A7Q34074109-D4B6346F-0D2D-48C4-A753-6D359F0BA1F6Q34242174-F902C6C9-0A59-4331-BB2E-27DB4FA0D77AQ34524484-B9C2C48A-6D4D-4C37-B2F3-F6D0F1927B6AQ34732996-B1A97067-9E6E-42F9-B6A8-1F064C11F683Q35030992-14B89FEA-E8C6-496A-9DEC-53FE777EE0D0Q35150612-BA42FEEA-AB1A-4EF9-A744-E7460A98D6A5Q35181071-CEE5E507-73F9-4F83-B149-F6B8B0E11B58Q35860140-FDCE2D7C-70F7-421A-8207-72558E2B7B30Q36164751-7D5F2F68-77D5-41D7-8EE8-45F7B5576A44Q36337525-07D30008-4FE2-4FDD-9C94-8633B888E19BQ37335164-639EAEC1-6D5D-4D30-9882-6A36C5A1AE22Q37886988-04690C50-1C7C-4B63-9F4C-BEC7F8C6475FQ38127260-0E551918-B9B7-4CB8-B40B-C92D1D553701Q39411240-869B8787-8D2A-4EB2-BB03-75C0463EAA6BQ40020050-25FBE870-665C-4A30-82F9-F6B7FE3C7C14Q41623583-358617E7-9E1B-4639-B916-5387D1B18160Q41811874-BA808379-4B54-4325-89B8-DA39EFC840E2Q42283126-5DCA2C37-D57F-4ABA-83D2-02CCC5D484E4Q46808883-E8357DE6-25B0-4561-BDD6-7AD82E80EA24Q57666236-B93C5471-308A-4EC1-8A86-2C440E255EF7
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Psoriasin (S100A7)
@ast
Psoriasin (S100A7)
@en
Psoriasin (S100A7)
@en-gb
Psoriasin (S100A7)
@nl
type
label
Psoriasin (S100A7)
@ast
Psoriasin (S100A7)
@en
Psoriasin (S100A7)
@en-gb
Psoriasin (S100A7)
@nl
prefLabel
Psoriasin (S100A7)
@ast
Psoriasin (S100A7)
@en
Psoriasin (S100A7)
@en-gb
Psoriasin (S100A7)
@nl
P2093
P1476
Psoriasin (S100A7)
@en
P2093
E R Leygue
L C Murphy
P H Watson
P304
P356
10.1016/S1357-2725(97)00066-6
P407
P577
1998-05-01T00:00:00Z